LAKE FOREST, Ill.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative cancer therapies, is pleased to announce its support of a clinical trial evaluating SIR-Spheres microspheres at the Goshen Cancer Institute at Goshen Health System in Goshen, Ind. The trial will evaluate the efficacy of Sirtex’s SIR-Spheres microspheres and chemotherapy as a first-line treatment for patients with colorectal cancer that has metastasized to the liver. Seza Gulec, M.D., F.A.C.S., Director of the Goshen Cancer Institute’s Hepatic Oncology Program is the principle investigator for the study.
